The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, ...

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical ...

The O'Hern sisters helped each other fight breast cancer. Now they're walking in the 2025 Kentucky Oaks Survivors Parade at ...

D Molecular Therapeutics (NASDAQ:FDMT) said on Thursday that the U.S. FDA has granted the regenerative medicine advanced ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Hereditary angioedema (HAE) is characterized by unpredictable and often debilitating edema episodes that can occur at seemingly random locations across the body. One area that can be very severely ...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE ... it initiates the cascade of events leading ...

There may be a genetic component to AMD, although researchers continue ... Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: a systematic review ...

Hereditary angioedema is characterized by unpredictable swelling involving the face, oropharynx, extremities, or abdomen, without hives or pruritus. Laryngeal attacks carry a risk of asphyxiation, ...